1Maccioni RB, Munoz JP, Barbeito L . The molecular bases of Alzheimerg disease and other neurodegenerative disorders [J]. Arch Med Res,2001 ;32(5) :367-81.
2Kem WR, Mahnir VM, Papke RL et al. Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors[J]. J Pharmacol Exp Ther01997 ;283 (3) :979-92.
3Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease : studies with DMX-BA ( GTS-21 ) [J]. Behav Brain Res,2000 ; 113 ( 1-2 ) : 169-81.
4Davies P, Feisullin S. Postmortem stability of α-bungarotoxin binding sites in mouse and human brain [J]. Brain Res,1981 ;216:449-54.
5Meyer EM, Tay ET, Papke RL et al . 3-[2,4-Dimethoxybenzylidene] anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner[J]- Brain Res, 1997 ;768 ( 1-2 ) :49-56.
6Briggs CA, Anderson D J, Brioni JD et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitroand in vivo [J]. Pharmacol Biochem Behav,1997 ;57(1-2) :231-41.
7Meyer EM, King MA, Meyers C. Neuroprotective effects of 2,4-dime-thoxyben zylidene anabaseine ( DMXB ) and tetrahydroaminoacridine(THA) in neocortices of nucleus basalis lesioned rats [J]. Brain Res,1998;786(1-2) :252-4.
8Meyer EM, Kuryatov A, Gerzanich Vet al. Analysis of 3-(4-hydroxy,2-Methoxybenzylidene) anabaseine selectivity and activity at human andrat alpha-7 nicotinic receptors. Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis [J]. Br J Pharmacol.2002:137(1) :49-61 .
9Cuevas J, Berg DK. Mammalian nicotinc receptors with α7 subunits thatslowly desensitize and rapidly recover from α-bungarotoxin blockade [J].J Neurosci, 1998 : 18:8228-35.
10Azuma R, Minami Y, Satoh T. Simultaneous determination of GTS-21 and its metabolite in rat plasma by high-performance liquid chromatography using solid-phase extraction [J]. J Chromatogr B Biomed Appl,1996 ;686(2 ) :229-34.
